Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer

Inclusion Criteria:

* Patients with newly diagnosed stage I (T\>1cm), II or III triple negative breast cancer who have not had definitive breast surgery or received systemic chemotherapy
* The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor and progesterone receptor staining present in ≤ 10% of invasive cancer cells by Immunohistochemistry.
* HER- 2 negativity will be based on the current ASCO-CAP guidelines for HER testing
* No prior chemotherapy, endocrine therapy or radiation therapy with therapeutic intent for this cancer
* Female subjects age 18 - 70 years
* ECOG Performance Status of 0-1
* Adequate organ and marrow function as defined below:

  * Leukocytes ≥ 3,000/uL
  * Absolute neutrophil count ≥ 1500/uL
  * Platelets ≥ 100,000/uL
  * Total bilirubin ≤ 1.5mg/dL
  * AST(SGOT)/ALT(SPGT) ≤ 2 x institutional upper limit of normal
  * Creatinine ≤ 1.5mg/dl and/or Creatinine Clearance ≥ 60mL/min
  * Serum albumin ≥ 3.0 g/dL
* Women of child-bearing potential must agree to use adequate contraception
* Pretreatment lab values must be performed within 14 days of treatment initiation, and other baseline studies performed within 30 days prior to registration
* Subjects should have LVEF ≥ 50% by echocardiogram or MUGA scan performed within 4 weeks prior to treatment initiation
* Subjects should have breast and axillary imaging with breast MRI or breast and axillary ultrasound within 4 weeks prior to treatment initiation
* Subjects with clinically/radiologically abnormal axillary lymph nodes should have pathological confirmation of disease with image guided biopsy/fine needle aspiration.
* Subjects must be already enrolled in P.R.O.G.E.C.T observational registry
* Staging to rule out metastatic disease is recommended for subjects with clinical stage III disease
* Subjects with bilateral disease are eligible if they meet other eligibility criteria.
* Neuropathy: No baseline neuropathy grade \> 2

Exclusion Criteria:

* Current or anticipated use of other investigational agents
* Subject has received chemotherapy, radiotherapy or surgery for the treatment of breast cancer
* Subject with metastatic disease
* History of allergic reactions to compounds of similar chemical or biologic composition to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study
* Subjects with inflammatory breast cancer
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements
* Subject is pregnant or nursing
* Subjects with concomitant or previous malignancies within the last 5 years. Exceptions include: adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and ductal carcinoma in situ (DCIS).
* Ejection Fraction \<50% on ECHO or MUGA
* Cardiac function: Subjects with congestive heart failure, myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack within the past 12 months, uncontrolled hypertension (Systolic BP\>160 or Diastolic BP\>90), uncontrolled or symptomatic arrhythmia, or grade ≥ 2 peripheral vascular disease